Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease-Reference-Cited by-同舟云学术

Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease

Published:1989-07 Issue:1 Volume:97 Page:38-41
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Allgayer Hubert,Ahnfelt Niels O.,Kruis Wolfgang,Klotz Ulrich,Frank-Holmberg Katharina,Söderberg Hellmut N.A.,Paumgartner Gustav

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference24 articles.

1. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensitization in cases of hypersensitiveness to sulpha;Svartz;Acta Med Scand,1948

2. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine;Peppercorn;J Pharmacol Exp Ther,1972

3. Azo reduction of salicyl-azosulphapyridine in germ-free and conventional rats;Schröder;Xenobiotica,1973

4. An experiment to determine the active moiety of sulphasalazine;Azad Khan;Lancet,1977

5. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine;Van Hees;Gut,1980

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches;Microbiome Research Reports;2023-09-26

2. 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis;Scientific Reports;2023-07-28

3. Efficient colonic drug delivery in domestic pigs employing a tablet formulation with dual control concept;Journal of Controlled Release;2023-06

4. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease;Frontiers in Microbiology;2023-02-23

5. Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis;Therapeutic Drug Monitoring;2023-02-22